Shockwave Medical Inc (NASDAQ:SWAV) Director Antoine Papiernik sold 650,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $34.35, for a total value of $22,327,500.00.

SWAV opened at $31.54 on Friday. The company has a quick ratio of 8.59, a current ratio of 9.13 and a debt-to-equity ratio of 0.10. The company has a 50 day simple moving average of $42.35. Shockwave Medical Inc has a 12 month low of $24.58 and a 12 month high of $68.39.

Shockwave Medical (NASDAQ:SWAV) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.17. The business had revenue of $10.00 million during the quarter, compared to analyst estimates of $8.29 million. Shockwave Medical’s quarterly revenue was up 334.8% on a year-over-year basis. As a group, research analysts forecast that Shockwave Medical Inc will post -2.51 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Salomon & Ludwin LLC acquired a new stake in shares of Shockwave Medical in the 2nd quarter valued at approximately $43,000. Advisory Services Network LLC purchased a new position in Shockwave Medical in the 1st quarter valued at approximately $26,000. Advisor Group Inc. purchased a new position in Shockwave Medical in the 2nd quarter valued at approximately $56,000. Capital Investment Advisory Services LLC increased its stake in Shockwave Medical by 40.0% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 4,375 shares of the company’s stock valued at $219,000 after purchasing an additional 1,250 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. increased its stake in Shockwave Medical by 1,350.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,450 shares of the company’s stock valued at $83,000 after purchasing an additional 1,350 shares in the last quarter. 47.96% of the stock is owned by institutional investors and hedge funds.

Several analysts have recently commented on SWAV shares. Canaccord Genuity raised their price target on Shockwave Medical from $50.00 to $65.00 and gave the company a “positive” rating in a report on Tuesday, June 18th. Bank of America reissued a “neutral” rating and issued a $44.00 price target on shares of Shockwave Medical in a report on Thursday, June 13th. Finally, Zacks Investment Research cut Shockwave Medical from a “hold” rating to a “sell” rating in a report on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $43.50.

About Shockwave Medical

ShockWave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases worldwide. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease.

Recommended Story: Stock Symbols Definition, Examples, Lookup

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.